- Third quarter results to be released after market close on October 31,
MISSISSAUGA, Oct. 29, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio
of products for the topical treatment of pain and the development of
its immune modulating drug candidate WF10, today announced it will host
a conference call on Thursday, November 1, 2012 at 8:30 a.m. (ET) to
discuss its 2012 third quarter financial results.
Nuvo invites all interested parties to participate. You can join the
call by dialing 647-427-7450 or 1-888-231-8191. Please call in 15
minutes prior to the call to secure a line. You will be placed on hold
until the conference call begins.
A question and answer session will follow, at which time the operator
will direct participants as to the correct procedure for submitting
questions. A taped replay of the conference call will be available
until Thursday, November 8, 2012 by calling 416-849-0833 or
1-855-859-2056, reference number 30403526.
A live audio webcast of the conference call will be available through www.nuvoresearch.com. Please connect at least 15 minutes prior to the conference call to
ensure adequate time for any software download that may be required to
listen to the webcast.
About Nuvo Research Inc.
Nuvo Research is a publicly traded, Canadian specialty pharmaceutical
company, headquartered in Mississauga, Ontario. The Company is
building a portfolio of products for the treatment of pain through
internal research and development and by in-licensing and acquisition.
The Company's product portfolio includes Pennsaid®, Pliaglis® and Synera®. Pennsaid, a topical nonsteroidal anti-inflammatory drug (NSAID), is
used to treat the signs and symptoms of osteoarthritis of the knee(s).
Pennsaid is sold in the United States by Mallinckrodt Inc., the
Pharmaceuticals business of Covidien, in Canada by Paladin Labs Inc.
and in several European countries. Pliaglis is a topical local
anesthetic cream which provides topical local analgesia for superficial
dermatological procedures. The Company has licensed worldwide
marketing rights to Pliaglis to Galderma Pharma S.A., a global
pharmaceutical company specialized in dermatology. Synera is a topical
patch that combines lidocaine, tetracaine and heat, approved in the
United States to provide local dermal analgesia for superficial venous
access and superficial dermatological procedures and in Europe, for
surface anaesthesia of normal intact skin. Nuvo currently markets
Synera in the United States and its licensing partner, Eurocept
International B.V., has initiated a pan-European launch of Synera
(under the name Rapydan®) in several European countries. The Company is also developing the
compound WF10, for the treatment of immune related diseases.
This document contains forward-looking statements. Some forward-looking
statements may be identified by words like "expects", "anticipates",
"plans", "intends", "indicates" or similar expressions. These
forward-looking statements, by their nature, necessarily involve risks
and uncertainties that could cause actual results to differ materially
from those contemplated by the forward-looking statements. Nuvo
considers the assumptions on which these forward-looking statements are
based to be reasonable at the time they were prepared, but caution that
these assumptions regarding future events, many of which are beyond the
control of the Company, may ultimately prove to be incorrect. Factors
and risks, which could cause actual results to differ materially from
current expectations, are discussed in the Annual Report, as well as in
Nuvo's Annual Information Form for the year ended December 31, 2011.
Nuvo disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information or
future events, except as required by law. For additional information on
risks and uncertainties relating to these forward looking statements,
investors should consult the Company's ongoing quarterly filings,
annual report and Annual Information Form and other filings found on
SEDAR at www.sedar.com.
SOURCE Nuvo Research Inc.